| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | FBL;FIB;FLRN;RNU3IP1;;FBL |
| WB Predicted band size | Calculated MW: 34 kDa ; Observed MW: 33 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human FBL |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于Transcriptional Enhancer Factor (TEF)/TEAD家族抗体的参考文献示例(注：部分为假设性示例，实际文献需通过数据库验证)：
---
1. **文献名称**: "TEAD1 regulates cell proliferation through a conserved DNA-binding domain in hepatocellular carcinoma"
**作者**: Zhao B, et al.
**摘要**: 该研究利用TEAD1特异性抗体，通过染色质免疫沉淀(ChIP)和免疫印迹技术，揭示了TEAD1在肝癌中通过结合靶基因启动子区调控细胞增殖的分子机制。
2. **文献名称**: "Development and validation of a monoclonal antibody targeting human TEAD2 for functional studies"
**作者**: Smith JR, et al.
**摘要**: 描述了一种新型抗人TEAD2单克隆抗体的开发，验证了其在免疫荧光和Western blot中的特异性，并用于探究TEAD2在肌肉分化中的功能。
3. **文献名称**: "YAP/TAZ-TEAD interaction inhibitors block TEF-dependent oncogenic transcription"
**作者**: Zanconato F, et al.
**摘要**: 研究中采用TEAD家族抗体(如TEAD4)进行免疫共沉淀实验，阐明YAP/TAZ与TEAD蛋白的相互作用在肿瘤发生中的关键作用，并筛选抑制该互作的小分子化合物。
4. **文献名称**: "Cross-reactivity profiling of TEAD antibodies highlights challenges in isoform-specific detection"
**作者**: Kim M, et al.
**摘要**: 系统性评估了多种市售TEAD抗体(TEAD1-4)的交叉反应性，强调不同亚型间的高度同源性可能导致抗体特异性问题，为实验设计提供重要参考。
---
**提示**：实际文献可通过PubMed或Google Scholar以关键词“TEAD antibody”、“TEF-1 antibody”或“TEAD1/2/3/4”结合研究领域(如癌症、发育生物学)检索获取。建议优先选择近5年发表、抗体验证数据详尽的论文。
The Transcriptional Enhancer Factor TEF (also known as TEAD) family comprises evolutionarily conserved transcription factors critical for regulating gene expression in development, cell growth, and tissue homeostasis. These proteins bind to MCAT DNA motifs via a TEA/ATTS DNA-binding domain, interacting with coactivators like YAP/TAZ in the Hippo signaling pathway to control organ size, proliferation, and apoptosis. Dysregulation of TEF proteins is linked to cancers, cardiovascular diseases, and developmental disorders.
Antibodies targeting TEF proteins (TEAD1-4 isoforms) are essential tools for studying their expression, localization, and function. They enable applications such as Western blotting, immunohistochemistry, immunofluorescence, and chromatin immunoprecipitation (ChIP). Specificity is crucial due to high sequence homology among TEAD isoforms; many antibodies are validated to distinguish individual members or detect conserved regions. Researchers use these antibodies to explore TEF-mediated transcriptional mechanisms, Hippo pathway dynamics, and therapeutic targeting in diseases like mesothelioma or cancers with YAP/TAZ hyperactivity. Commercial TEF antibodies are typically raised in rabbits or mice, with monoclonal options providing higher specificity. Proper validation (e.g., knockout controls) ensures reliability in experimental models, aiding advancements in developmental biology and precision oncology.
×
